Human lymphoblastoid interferon (Wellferon) in primary therapy of two children with condylomata acuminata.
Human lymphoblastoid interferon (Wellferon) was administered parenterally to two prepubertal girls as primary therapy for genital condylomata acuminata. One child probably had contracted the disease as the result of sexual molestation. Both patients experienced minimal side effects during therapy and underwent complete remission within six weeks. These cases support use of interferon as primary therapy in young patients with extensive condylomata and in those who may have contracted the disease as the result of sexual abuse.
D002648:Child; D003218:Condylomata Acuminata / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D027383:Papillomaviridae; D010502:Perineum; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy*
D007370:Interferon Type I